Hinge Health's Fresh Attention Is Real — and Already Priced In

The fresh attention on Hinge Health is not hype. On August 4, the digital musculoskeletal-care company reported second-quarter revenue of $212.8 million, up 53% from a year earlier — and, in the number that matters, generated about $100 million of free cash flow in the quarter, roughly triple the year-ago level. Wall Street responded by pushing the stock to near its highs, capping a rally of about 90% so far this year. The question for anyone intrigued by that move is whether the market is paying for real, durable improvement or getting ahead of a good quarter.

The story flipped from "money-losing IPO" to "cash machine"

Hinge Health sells virtual physical therapy and musculoskeletal (MSK) care to nearly 3,000 clients, pairing an AI-guided app with wearable sensors to treat joint and back pain at a fraction of surgery and imaging costs. It went public in May 2025 at $32, a down-round debut that valued the business at about $3 billion, and spent its first public months trading near its IPO. The stock's 52-week low is about $30.

What changed is not the pitch but the economics. In Q2 2025 the company reported a GAAP loss of $13.10 per share, distorted by a one-time $591 million stock-based-compensation charge tied to the IPO. A year later it reported GAAP income of $0.52 per share — a swing that inflates the story if you only see it at that level, but the operating picture underneath is genuinely stronger. Non-GAAP operating income rose 136% to $61.5 million, the non-GAAP operating margin improved to 29% from 19%, and free cash flow tripled. Gross margin sits near 86%.

That inflection matters more than any single line item, because it changes the kind of company Hinge is. An investor funding a loss-making disruptor has to underwrite future dilution and an unknown "are they ever profitable?" outcome. A company throwing off cash equal to roughly 40% of sales, with only about $7 million of annual capital expenditure in an asset-light model, stops being a bet and starts being an earnings stream — and the market re-rates accordingly.

Management stacked the news, and the tax on it

Hinge did not stop at beating its own forecast (it entered Q2 guiding to ~$195 million of revenue and delivered $212.8 million). It raised full-year guidance to $856–860 million, about 46% growth at the midpoint, guided to a 28% non-GAAP operating margin, added $300 million to its share-repurchase authorization, and signed a $105 million cash deal to buy Cylinder Health, a virtual digestive-care company, pushing into gastrointestinal care — a category that affects roughly one in four U.S. adults and accounts for an estimated $135 billion in annual spend, with an integrated GI program set to launch in 2027.

This is the part to be careful about. Every item is real, but they all point the same direction: up, and now. A buyback after a 90% run is management spending cash to keep the lid on a fast-climbing share count at an elevated price, and a first acquisition introduces integration and execution risk in a new clinical category. The news is good; the timing of the news, after the stock already re-rated, is what a disciplined buyer has to discount.

A ~$7 billion valuation is paying for continuation

At $88, Hinge trades near its $95.57 52-week high, with a market capitalization around $7.1 billion. On the trailing twelve months that is roughly 10x sales, about 65-70x trailing earnings, and roughly 25x trailing free cash flow. On 2026's raised guidance, forward sales are about 8x.

Read that honestly against the persona's usual setup: this is not a beaten-down value gap. The market has come around to Hinge's improving fundamentals — the multiple did the moving, not the price catching up to the numbers. So the burden of proof flips. A nearly 50% grower with a 40% free-cash-flow margin at roughly 25x cash flow is expensive but defensible if the growth compounds. It becomes fragile if growth decelerates toward low double digits or if margins erode as the GI business integrates — because a stock that has already re-rated sharply has no leftover pessimism to release, only expectations to meet.

The observable number to anchor on is the third-quarter guide of $223–225 million in revenue, about 45% growth. Hinge has now beaten and raised for consecutive quarters, so the market expects more of the same. The invalidation to watch is the same thing that built the case: if the ~45% growth decelerates or the ~40% free-cash-flow margin slips, a ~65-70x earnings multiple compresses fast, and there is no contrarian cushion beneath the current price.

For a watcher, the honest read is that the fresh attention is fundamentally earned — this is not narrative-driven noise — but the easy gains from the re-rating are largely behind the stock. The lower-risk entry was a year ago near $30, not at $88. The disciplined posture is patience on a pullback rather than chasing the continuation, while treating each quarterly beat-and-raise as the test that decides whether the multiple is justified. The company earned the attention; the price now has to prove it can keep earning the next 45%.